Dr Jennifer Schneider is an experienced international life science executive and leader focused on the development of anti-infective therapeutics and vaccines, who throughout her career has secured more than $5B through funding and strategic partnerships. As CEO of Centauri Therapeutics, Jennifer has been instrumental in leading the Company through several major milestones, including closing a £30M Series A raise, and the selection of Centauri’s first clinical candidate to treat Gram-negative bacterial infections.
Specialising in antibiotic policy, strategic partnerships and commercialisation, Jennifer has spent more than 20 years supporting companies, universities and NGOs, and is actively involved in international discussions around market creation and access, and novel payment methods. Prior to Centauri, Jennifer was Executive Officer for the Global Antibiotic Research & Development Partnership (GARDP), North America.
Jennifer holds a PhD in Molecular Biology from the University of Notre Dame, and an MPH in Epidemiology and International Health from the University of Michigan.